Perioperative pembrolizumab plus metastasis-directed therapy versus MDT alone in patients with oligometastatic renal cell carcinoma: The randomized phase II PE-PE trial
Feasibility and reproducibility of PD-L1 assessment within CARE1: A phase III, randomized, biomarker-driven pragmatic trial to optimize first-line treatment in patients with metastatic clear-cell renal cell carcinoma
Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era
Management of lymph node–positive renal cell carcinoma: Updated recommendations from the European Association of Urology renal cell carcinoma guidelines panel
What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials